{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:15:00Z","timestamp":1788243300960,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Approximately 10%\u201330% patients with biopsy-proven membranous nephropathy (MN) are seronegative for anti-phospholipase A2 receptor antibody (PLA2R-Ab). Only ~5% are truly non-PLA2R MN and are associated with alternative antigens (e.g., THSD7A), while the majority represent false-negative PLA2R-associated MN due to insufficient assay sensitivity. Accurate noninvasive diagnostic tools for this population are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective risk stratification study enrolled 692 PLA2R Ab negative patients in the derivation cohort and 333 patients in an independent external validation cohort. We developed and validated an interpretable VotingSoft machine learning model based on 13 key clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The model achieved excellent risk stratification performance: AUC 0.878 (95% confidence interval (CI): 0.850\u20130.903) in five-fold cross-validation, 0.894 (95% CI: 0.854\u20130.930) in the internal test set, and 0.905 (95% CI: 0.867\u20130.935) in the external validation cohort. The model showed a specificity of 0.819, sensitivity of 0.764, and negative predictive value of 0.876. Key predictors were PLA2R Ab level, eGFR, age, and serum albumin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multicenter interpretable machine learning model provides an auxiliary tool for risk stratification of PLA2R-Ab-negative membranous nephropathy (MN) using routine clinical indicators. Its high specificity may facilitate early risk stratification; however, renal biopsy remains the gold standard for definitive pathological diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1906174","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:34:15Z","timestamp":1788240855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk prediction of PLA2R-Ab-negative membranous nephropathy: an interpretable multicenter machine learning model"],"prefix":"10.3389","volume":"17","author":[{"given":"Keyan","family":"Qian","sequence":"first","affiliation":[{"name":"Xinxiang Key Laboratory of Microfluidic Immunodiagnosis for Kidney Diseases, Kidney Disease Hospital, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Niu","sequence":"additional","affiliation":[{"name":"Network and Information Center, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Li","sequence":"additional","affiliation":[{"name":"Network and Information Center, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhan","family":"Yang","sequence":"additional","affiliation":[{"name":"Network and Information Center, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of General Practice, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Dang","sequence":"additional","affiliation":[{"name":"Xinxiang Key Laboratory of Microfluidic Immunodiagnosis for Kidney Diseases, Kidney Disease Hospital, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhao","family":"Li","sequence":"additional","affiliation":[{"name":"Xinxiang Key Laboratory of Microfluidic Immunodiagnosis for Kidney Diseases, Kidney Disease Hospital, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xinxiang Central Hospital, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Xinhua Hospital, Henan Province","place":["Anyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Xinxiang Key Laboratory of Microfluidic Immunodiagnosis for Kidney Diseases, Kidney Disease Hospital, The First Affiliated Hospital of Henan Medical University, Henan Province","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.25259\/ijn_317_23","article-title":"An updated review of membranous nephropathy","volume":"34","author":"Efe","year":"2024","journal-title":"India J Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.18021120","article-title":"HLA alleles and prognosis of PLA2R-related membranous nephropathy","volume":"16","author":"Le","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.032","article-title":"Phospholipase A2 receptor-positive membranous nephropathy detected by laser microdissection and mass spectrometry in patients negative by immunofluorescence for phospholipase A2 receptor on kidney biopsy","volume":"108","author":"Zand","year":"2025","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845767","article-title":"Novel biomarkers in membranous nephropathy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1685738","article-title":"Clinical study of PLA2R epitope spreading for predicting proteinuria remission in primary membranous nephropathy","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1328579","article-title":"Prediction of immunotherapy response in idiopathic membranous nephropathy using deep learning-pathological and clinical factors","volume":"15","author":"Wei","year":"2024","journal-title":"Front Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12711","article-title":"Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation","volume":"30","author":"Gupta","year":"2016","journal-title":"Clin Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2215\/cjn.0000000671","article-title":"Noninvasive diagnostic strategies for membranous nephropathy in the nephrotic syndrome study network","volume":"20","author":"Zee","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019050538","article-title":"Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/ijnrd.s176665","article-title":"Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults","volume":"11","author":"Wu","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281726","article-title":"Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy","volume":"18","author":"Ragy","year":"2023","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1038\/s41598-024-53445-x","article-title":"Diagnostic value of renal biopsy in anti-phospholipase A2 receptor antibody-positive patients with proteinuria in China","volume":"14","author":"Lu","year":"2024","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf012","article-title":"PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy","volume":"40","author":"Ragy","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.04710420","article-title":"Systematic review and meta-analysis of native kidney biopsy complications","volume":"15","author":"Poggio","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.11.028","article-title":"A target antigen\u2013based approach to the classification of membranous nephropathy","volume":"96","author":"Bobart","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7150\/thno.123035","article-title":"Antibody-induced internalization and degradation of PLA2R amplifies CD4+ T cell activation","volume":"16","author":"Liu","year":"2026","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-025-00980-z","article-title":"Antigens in membranous nephropathy: discovery and clinical implications","volume":"21","author":"Sethi","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-00971-w","article-title":"Towards optimizing use of PLA2R antibody testing in membranous nephropathy","volume":"34","author":"Hogan","year":"2021","journal-title":"J Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1816719","article-title":"Identification of antibodies against phospholipase A2 receptor peptides in PLA2R-associated membranous nephropathy with negative circulating anti-PLA2R antibodies","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2020.03.022","article-title":"How machine learning will transform biomedicine","volume":"181","author":"Goecks","year":"2020","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13054-021-03724-0","article-title":"Machine learning model for early prediction of acute kidney injury (AKI) in pediatric critical care","volume":"25","author":"Dong","year":"2021","journal-title":"Crit Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05444-0","article-title":"Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease","volume":"64","author":"Chan","year":"2021","journal-title":"Diabetologia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2020.03.005","article-title":"Opening the black box: interpretable machine learning for geneticists","volume":"36","author":"Azodi","year":"2020","journal-title":"Trends Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2015020181","article-title":"Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of anti-phospholipase A2 receptor autoantibodies","volume":"26","author":"Brenchley","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1186\/s12887-025-06337-6","article-title":"Development and validation of machine learning models for predicting bronchopulmonary dysplasia risk in preterm neonates based on antenatal determinants: a retrospective cohort study","volume":"25","author":"Guo","year":"2025","journal-title":"BMC Pediatr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2022.01.011","article-title":"Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice","volume":"145","author":"Berkelmans","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110317","article-title":"Membranous nephropathy: mechanistic insights and therapeutic perspectives","volume":"120","author":"Hua","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906174\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:34:16Z","timestamp":1788240856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906174\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1906174"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1906174","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1906174"}}